Trial reportDrug design, development and therapy2026
Ultrasound-Guided Femoral Nerve Block with Esketamine Adjuvant for Postoperative Analgesia in Total Knee Arthroplasty-A Randomized, Double-Blind, Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methodological Concerns Regarding the Use of Esketamine as an Adjuvant in Femoral Nerve Block for Total Knee Arthroplasty [Letter].Drug design, development and therapy · 2026Article
- Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Response to Letter].Drug design, development and therapy · 2026Article
- Interpreting Perineural Esketamine for Analgesia After Total Knee Arthroplasty: Methodological and Reporting Considerations [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the analgesic effect and complication profile of ultrasound-guided femoral nerve block (FNB) with esketamine as an adjuvant to ropivacaine in patients undergoing total knee arthroplasty (TKA). Methods: This was a prospective, randomized, double-blind, controlled clinical trial. Sixty patients undergoing elective TKA were randomized 1:1 into Group A (n=30) and Group B (n=30). Group A received 20 mL of 0.25% ropivacaine for ultrasound-guided FNB, whereas Group B received 20 mL of 0.25% ropivacaine combined with 0.5 mg/kg esketamine for identical FNB. All patients received combined general anesthesia and FNB. Postoperative visual analogue scale (VAS) pain scores at 2, 4, 6, 8, 10, and 12 h, 24-hour sufentanil consumption, incidence of postoperative nausea and vomiting (PONV), and other adverse events were documented. Results: Baseline characteristics including age, height, weight, ASA physical status, gender composition, and operation duration were comparable between the two groups (all P>0.05). The VAS score at 10 h postoperatively was significantly lower in Group B than in Group A (P=0.026), while no significant differences were detected at other time points (all P>0.05). Total 24-hour sufentanil consumption was significantly reduced in Group B compared with Group A (P<0.001). The incidence of PONV did not differ significantly between the two groups (P=0.467). Conclusion: Ultrasound-guided femoral nerve block (FNB) combined with esketamine and ropivacaine relieved postoperative pain at 10 hours and reduced opioid consumption in patients undergoing total knee arthroplasty (TKA), with no increase in adverse events. This regimen can serve as a safe analgesic option for TKA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.